Marianthi Foundation

Marianthi Foundation

The Marianthi Foundation was established in 1994 by P. Roy Vagelos and his wife Diana, formalizing a family philanthropic tradition anchored by the wealth Roy Vagelos generated as CEO of Merck and later as Chairman of Regeneron Pharmaceuticals. Named after Roy Vagelos's mother, the foundation directs capital primarily toward university-level educational projects, biomedical research, and environmental causes, reflecting the family's scientific and academic values. While grantmaking defines its public identity, the foundation maintains an active investment posture concentrated in buyout strategies across multiple asset classes. Public record indicates holdings in commercial real estate and private debt within the United States. A substantial portion of the foundation's balance sheet derives from P. Roy Vagelos's long-standing relationship with Regeneron, where he has served as Chairman and accumulated significant equity. The foundation's investment activity operates alongside related philanthropic vehicles including the Pindaros Foundation, suggesting a family-office-style architecture beneath the grantmaking surface. The foundation is governed by a tight family board. Diana T. Vagelos serves as Vice President and Treasurer while also holding a trustee role at Barnard College. The next generation is represented through directors Andrew Vagelos and Cynthia Vagelos Roberts. P. Roy Vagelos's professional affiliations — including membership in the National Academy of Sciences and the American Academy of Arts and Sciences — extend the foundation's reach into elite scientific and institutional networks that can inform both grantmaking and investment sourcing. The structural differentiator is the fusion of a scientist-CEO's investment judgment with a grantmaking mission. Unlike many foundations that outsource investment decisions entirely to an OCIO, the Marianthi Foundation appears to blend direct buyout exposure, real assets, and private credit alongside concentrated public-company equity from Roy Vagelos's board-level corporate relationships. This hybrid posture — part family office, part institutional foundation — is unusual for a vehicle of its reported scale, and it ties the foundation's financial durability directly to Roy Vagelos's presence and Regeneron's trajectory.